

Urology
MD, Associate Professor of Urology; Co-Chair, Cancer Liaison Committee, Oncology, Co-Chair, NCCN Guidelines Committee on Prostate Cancer Early Detection, Division Chief, Division of Urology at VA Connecticut Healthcare System, Urology, Director, Urology…
Dr. Preston C. Sprenkle specializes in the treatment of urologic cancers, primarily prostate cancer, but also including kidney cancer, bladder cancer, and testicular cancer.
Dr. Sprenkle has dedicated his career to using the latest technologies to improve prostate cancer diagnosis and treatment that minimizes the impact on a man's quality of life.
He was one of the first physicians nationwide to implement the use of the Artemis Device. This machine, introduced in 2009, allows a surgeon to use 3D ultrasound technology and merge it with even more precise magnetic resonance imaging (MRI) to accurately identify cancerous tumors.
“Skilled and experienced radiologists are rare for this relatively new technique,” Dr. Sprenkle explains. “At Yale, we are fortunate to have some of the world leaders in prostate MRI.”
Dr. Sprenkle is also a pioneer in “focal therapy,” which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This avoids many of the side effects—such as erectile dysfunction and incontinence—that may follow the removal of the whole prostate.
“Exciting technological advances are revolutionizing urology. Prostate cancer is very common and current treatments can majorly impact a man's sexual and urinary function,” Dr. Sprenkle says. “Developing ways to minimize the impact of prostate cancer diagnosis and treatment on a man's health and quality of life is tremendously rewarding.”
Dr. Sprenkle believes in working with patients to come up with individualized treatment plans. “I want my patients to feel that I hear their concerns and treat them like a person. I am pleased at the end of a long consultation when they feel like they understand their disease and their options.”
Selected publications from PubMed
Association between genomic classifier scores and initial management of localized prostate cancer in the United States.
Leapman MS, Wang R, Sprenkle PC, Kim IY, Loeb S, Seibert TM, Cooperberg MR, Gann PH, Ginsburg K, Catalona WJ, Dinan MA, Gross CP, Ma X
J Natl Cancer Inst. 2026 Aug 31 pii: djag247. doi: 10.1093/jnci/djag247.
Re-Evaluating the Role of Locoregional Therapy in Metastatic Prostate Cancer: A Review of Current Evidence and Evolving Clinical Approaches.
Ajjawi I, Sprenkle PC, Renzulli JF, Leapman MS
Urol Clin North Am. 2026 May;53(2):193-203 doi: 10.1016/j.ucl.2026.02.002.
Strong-Gradient Diffusion-Weighted Imaging of Prostate Cancer Using an Inside-Out Nonlinear Gradient Coil.
Zhang HZ, Elsaid NMH, Nixon TW, Dewdney A, Peters DC, Weinreb JC, Sprenkle PC, Constable RT, Galiana G
Magn Reson Med. 2026 May;95(5):2671-2688 doi: 10.1002/mrm.70252.
Sociodemographic Factors Associated With Tissue-based Genomic Testing for Prostate Cancer.
Diaz GM, Sivanesan N, Strachan S, Sohoni N, DuBois J, Zhao X, Sprenkle PC, Leapman MS
Urology. 2026 Apr;210:35-39 doi: 10.1016/j.urology.2025.12.004.
Association between baseline prostate MRI PI-RADS classification and risk of Gleason upgrade during active surveillance: a systematic review and meta-analysis.
Smani S, Sohoni N, Miszczyk M, Fazekas T, Rajwa P, Grimshaw AA, Sundaresan VM, Lokeshwar SD, Weinreb J, Sprenkle PC, Cooperberg MR, Seibert TM, Shariat SF, Catalona WJ, Leapman MS
World J Urol. 2026 Feb 15;44(1):169 doi: 10.1007/s00345-026-06278-4.

Surgery and Radiation therapy remain gold standard treatments for prostate cancer. Continued improvements in technique and technology further reduce the side effects associated with these very effective treatments.
With Boston Scientific
Published
Mar 2022

Dr. Preston C. Sprenkle performs a Perirectal Spacing for Prostate Cancer Therapy surgery to a 72 years old male using the SpaceOAR™ Hydrogel.
With Boston Scientific
Published
Jul 2020
Help your network discover Dr. Preston C. Sprenkle's clinical expertise.